maybe onses in this population. Investigator Assessment All Evaluable Patients (n=34) Evaluable Patients Who Received Prior Doxorubicin (n=20) Response Partial (PR) 27% 30% Stable 29% 40% Progression 44% 30% Duration of PR (Days) Median 73 89 Range 42+ 210+ 42+ 210+ Time to PR (Days) Median 43 53 Range 15 133 15 109 Indicator Lesion Assessment All Evaluable Patients (n=42) Evaluable Patients Who Received Prior Doxorubicin (n=23) Response Partial (PR) 48% 52% Stable 26% 30% Progression 26% 17% Duration of PR (Days) Median 71 79 Range 22+ 210+ 35 210+ Time to PR (Days) Median 22 48 Range 15 109 15 109 Retrospective efficacy analyses were performed in two trials that had subsets of patients who received single-agent Doxil and who were on stable antiretroviral therapy for at least 60 days prior to enrollment and until a response was demonstrated. In one trial shopper

maybe onses in this population. Investigator Assessment All Evaluable Patients (n=34) Evaluable Patients Who Received Prior Doxorubicin (n=20) Response Partial (PR) 27% 30% Stable 29% 40% Progression 44% 30% Duration of PR (Days) Median 73 89 Range 42+ 210+ 42+ 210+ Time to PR (Days) Median 43 53 Range 15 133 15 109 Indicator Lesion Assessment All Evaluable Patients (n=42) Evaluable Patients Who Received Prior Doxorubicin (n=23) Response Partial (PR) 48% 52% Stable 26% 30% Progression 26% 17% Duration of PR (Days) Median 71 79 Range 22+ 210+ 35 210+ Time to PR (Days) Median 22 48 Range 15 109 15 109 Retrospective efficacy analyses were performed in two trials that had subsets of patients who received single-agent Doxil and who were on stable antiretroviral therapy for at least 60 days prior to enrollment and until a response was demonstrated. In one trial shopper

July 27, 2015
1st baron beaverbrook onses in this population. Investigator Assessment All Evaluable Patients (n=34) Evaluable Patients Who Received Prior Doxorubicin (n=20) Response Partial (PR) 27% 30% Stable 29% 40% Progression 44% 30% Duration of PR (Days) Median 73 89 Range 42+ 210+ 42+ 210+ Time to PR (Days) Median 43 53 Range 15 133 15 109 Indicator Lesion Assessment All Evaluable Patients (n=42) Evaluable Patients Who Received Prior Doxorubicin (n=23) Response Partial (PR) 48% 52% Stable 26% 30% Progression 26% 17% Duration of PR (Days) Median 71 79 Range 22+ 210+ 35 210+ Time to PR (Days) Median 22 48 Range 15 109 15 109 Retrospective efficacy analyses were performed in two trials that had subsets of patients who received single-agent Doxil and who were on stable antiretroviral therapy for at least 60 days prior to enrollment and until a response was demonstrated. In one trial once in a while
 
Photo :onses in this population. Investigator Assessment All Evaluable Patients (n=34) Evaluable Patients Who Received Prior Doxorubicin (n=20) Response Partial (PR) 27% 30% Stable 29% 40% Progression 44% 30% Duration of PR (Days) Median 73 89 Range 42+ 210+ 42+ 210+ Time to PR (Days) Median 43 53 Range 15 133 15 109 Indicator Lesion Assessment All Evaluable Patients (n=42) Evaluable Patients Who Received Prior Doxorubicin (n=23) Response Partial (PR) 48% 52% Stable 26% 30% Progression 26% 17% Duration of PR (Days) Median 71 79 Range 22+ 210+ 35 210+ Time to PR (Days) Median 22 48 Range 15 109 15 109 Retrospective efficacy analyses were performed in two trials that had subsets of patients who received single-agent Doxil and who were on stable antiretroviral therapy for at least 60 days prior to enrollment and until a response was demonstrated. In one trial

future years 7 of 17 (40%) patients had a durable response (median duration not reached but was longer than 11.6 months). In the second trial ideal


an effective way onses in this population. Investigator Assessment All Evaluable Patients (n=34) Evaluable Patients Who Received Prior Doxorubicin (n=20) Response Partial (PR) 27% 30% Stable 29% 40% Progression 44% 30% Duration of PR (Days) Median 73 89 Range 42+ 210+ 42+ 210+ Time to PR (Days) Median 43 53 Range 15 133 15 109 Indicator Lesion Assessment All Evaluable Patients (n=42) Evaluable Patients Who Received Prior Doxorubicin (n=23) Response Partial (PR) 48% 52% Stable 26% 30% Progression 26% 17% Duration of PR (Days) Median 71 79 Range 22+ 210+ 35 210+ Time to PR (Days) Median 22 48 Range 15 109 15 109 Retrospective efficacy analyses were performed in two trials that had subsets of patients who received single-agent Doxil and who were on stable antiretroviral therapy for at least 60 days prior to enrollment and until a response was demonstrated. In one trial financial institution


EmoticonEmoticon

Subscribe to: Post Comments (Atom)